• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.

作者信息

Rolfes Leoni, Pfeuffer Steffen, Ruck Tobias, Windhagen Susanne, Oschlies Ilske, Pavenstädt Hermann-Joseph, Angenendt Linus, Wiendl Heinz, Krämer Julia, Meuth Sven G

机构信息

From the Clinic of Neurology with Institute of Translational Neurology (L.R., S.P., T.R., H.W., J.K., S.G.M.), University Hospital Münster; Department of Neurology and Neurological Rehabilitation (S.W.), Hospital Osnabrück, Am Finkenhügel 1; Department of Pathology (I.O.), Hematopathology Section and Lymph Node Registry, University-Hospital Schleswig-Holstein, Campus Kiel; Department of General Internal Medicine (H.-J.P.), Nephrology, Hypertensiology, and Rheumatology, University Hospital Münster; and Department of Hematology (L.A.), Hemostaseology, Oncology, and Pneumology, University Hospital Münster, Germany.

出版信息

Neurol Neuroimmunol Neuroinflamm. 2019 Nov 8;7(1). doi: 10.1212/NXI.0000000000000638. Print 2020 Jan.

DOI:10.1212/NXI.0000000000000638
PMID:31704887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6865849/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfae/6865849/e410a5f90dd3/NEURIMMINFL2019021899f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfae/6865849/e410a5f90dd3/NEURIMMINFL2019021899f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfae/6865849/e410a5f90dd3/NEURIMMINFL2019021899f1.jpg

相似文献

1
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.1例接受阿仑单抗治疗的多发性硬化症患者发生特发性多中心Castleman病。
Neurol Neuroimmunol Neuroinflamm. 2019 Nov 8;7(1). doi: 10.1212/NXI.0000000000000638. Print 2020 Jan.
2
Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.在接受来那度胺治疗的复发性多发性硬化症患者中，第 3 个周期时发生肺栓塞。
Mult Scler Relat Disord. 2019 Oct;35:5-6. doi: 10.1016/j.msard.2019.06.032. Epub 2019 Jun 29.
3
Case of alemtuzumab-related alopecia areata management in MS.多发性硬化症中阿仑单抗相关斑秃的治疗病例
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 19;6(1):e516. doi: 10.1212/NXI.0000000000000516. eCollection 2019 Jan.
4
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.在使用阿仑单抗治疗多发性硬化症后，发生危及生命的自身免疫性温性溶血性贫血。
Mult Scler. 2018 May;24(6):811-813. doi: 10.1177/1352458517729766. Epub 2018 Jan 23.
5
A case of anaphylaxis to alemtuzumab.1例对阿仑单抗过敏的病例。
J Neurol. 2019 Mar;266(3):780-781. doi: 10.1007/s00415-019-09214-2. Epub 2019 Feb 4.
6
Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration. Lambert-Eaton 肌无力综合征与阿仑单抗给药相关。
Mult Scler Relat Disord. 2019 Jan;27:131-132. doi: 10.1016/j.msard.2018.10.015. Epub 2018 Oct 22.
7
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.阿仑单抗治疗多发性硬化症后侵袭性肺曲霉病的尸检诊断
Mult Scler. 2020 Jan;26(1):123-126. doi: 10.1177/1352458518813110. Epub 2019 Mar 18.
8
Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis.用阿仑单抗治疗多发性硬化症后出现严重的矛盾性疾病激活。
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 10;7(5). doi: 10.1212/NXI.0000000000000799. Print 2020 Sep.
9
Clinical observation during alemtuzumab administration.阿仑单抗给药期间的临床观察。
Mult Scler Relat Disord. 2020 Jan;37:101412. doi: 10.1016/j.msard.2019.101412. Epub 2019 Sep 25.
10
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.与阿仑单抗输注相关的急性冠状动脉综合征在多发性硬化症中的情况
Neurology. 2018 May 1;90(18):852-854. doi: 10.1212/WNL.0000000000005417. Epub 2018 Mar 30.

引用本文的文献

1
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.在接受阿仑单抗治疗的多发性硬化症患者中，既往疾病修正治疗对疗效和安全性结局的影响。
J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):1007-1013. doi: 10.1136/jnnp-2020-325304. Epub 2021 Mar 12.
2
Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient.病例报告：接受阿仑单抗治疗的多发性硬化症患者中发生成人斯蒂尔病。
Front Immunol. 2020 Aug 28;11:2099. doi: 10.3389/fimmu.2020.02099. eCollection 2020.
3
Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

本文引用的文献

1
Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.2例接受阿仑单抗治疗的多发性硬化患者发生噬血细胞性淋巴组织细胞增生症。
Neurology. 2018 May 1;90(18):849-851. doi: 10.1212/WNL.0000000000005420. Epub 2018 Mar 30.
2
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.阿仑单抗治疗复发型多发性硬化症（CARE-MS II）5年随访：疗效与安全性结果
Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.
3
Idiopathic multicentric Castleman's disease: a systematic literature review.
多发性硬化症免疫调节治疗策略的失败、中断或不确定临床试验：2015-2020 年更新。
BioDrugs. 2020 Oct;34(5):587-610. doi: 10.1007/s40259-020-00435-w.
4
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.1例接受阿仑单抗治疗的多发性硬化症患者发生特发性多中心Castleman病。
Neurol Neuroimmunol Neuroinflamm. 2019 Dec 5;7(1). doi: 10.1212/NXI.0000000000000657. Print 2020 Jan.
特发性多中心Castleman病：一项系统的文献综述
Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17.
4
The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.首例青少年 TAFRO 综合征报告，一种独特的多中心 Castleman 病临床病理变异型。
BMC Pediatr. 2014 Jun 2;14:139. doi: 10.1186/1471-2431-14-139.
5
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.阿仑单抗治疗缓解复发型多发性硬化症患者：一项疾病修饰治疗后随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
6
A novel strategy to reduce the immunogenicity of biological therapies.一种降低生物疗法免疫原性的新策略。
J Immunol. 2010 Jul 1;185(1):763-8. doi: 10.4049/jimmunol.1000422. Epub 2010 Jun 2.